Results 61 to 70 of about 30,492 (254)

Data sources for monitoring arthritis and other musculoskeletal conditions [PDF]

open access: yes, 2014
This report assesses the potential for existing data sources to improve our understanding of arthritis and other musculoskeletal conditions and highlights future opportunities for improving data for monitoring these conditions.

core  

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

open access: yesArthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora   +5 more
wiley   +1 more source

СONCENTRATION OF ANTI-INFLAMATORY CYTOKINES IN CELL CULTURE SUPERNATANTS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

open access: yesМедицинская иммунология, 2019
Juvenile idiopathic arthritis is a chronic inflammatory disease of the joints in children, mainly of autoimmune or auto-inflammatory nature. It is a heterogeneous group, which includes different subtypes of the disease. Different mechanisms may play role
I. M. Krivolapova   +2 more
doaj   +1 more source

Inosine‐Triphosphate‐Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients do not respond to it. Low inosine triphosphate pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated the role and underlying mechanisms of ITPA in vitro. Methods ITPA enzymatic activity
Sofia Sindici Forgiarini   +19 more
wiley   +1 more source

Oral Health Status among Group of Patients with Juvenile Idiopathic Arthritis According to Duration of Illness and Age Group in Iraq

open access: yesJournal of Baghdad College of Dentistry, 2016
Background: Juvenile idiopathic arthritis (JIA) is a chronic disease of childhood. Increased prevalence of periodontal disease and dental caries in juvenile idiopathic arthritis is due to difficulties in executing good oral hygiene.
Zainab Shallan, Nadia Aftan Al-Rawi
doaj   +1 more source

A Multifaceted Interplay Among Hemophagocytosis, Interleukin‐18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller   +16 more
wiley   +1 more source

The Temporomandibular Joint in Juvenile Idiopathic Arthritis, focusing on Quality of Life, Oral Microbiome and Intervention [PDF]

open access: yes, 2020
The temporomandibular joint (TMJ) is commonly involved in juvenile idiopathic arthritis (JIA), and may lead to impaired mouth opening, pain and facial growth disturbances.
Frid, Paula
core   +1 more source

Current Validated Clinical and Patient Reported Disease Outcome Measures in Juvenile Idiopathic Arthritis

open access: yesOpen Access Rheumatology: Research and Reviews, 2023
Erin Balay-Dustrude,1,2 Susan Shenoi1,2 1Department of Pediatrics, Division of Rheumatology, University of Washington, Seattle, WA, USA; 2Department of Pediatric Rheumatology, Seattle Children’s Hospital and Research Center, Seattle, WA ...
Balay-Dustrude E, Shenoi S
doaj  

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy